Femilift
FemiLift is a quick, safe, and non-surgical solution for the treatment of certain intimate conditions, such as urinary incontinence, vaginal laxity, dryness, recurrent infections, among others.
It is a procedure that alleviates these symptoms, whether caused by menopause, hormonal changes associated with cancer therapy, or post-partum conditions.
Treatment
FemiLift is a painless and minimally invasive treatment that, unlike other surgical procedures, can be performed in a clinic without the need to go to a hospital.
You can resume your daily routine immediately after the procedure, although it is recommended to avoid sexual intercourse for at least 72 hours. The vaginal tissue consists of collagen fibers, responsible for its contraction and flexibility.
FemiLift uses the clinically established CO2 laser technology, thereby contracting the existing fibers and stimulating the formation of new collagen, improving the function of the entire vaginal area.
The treatment is performed by Dr. Marta, who inserts a special probe into the vagina, directing the laser to the area to be treated.
This probe has two different anatomically adaptable sizes, for personal use only – being disposable. In turn, the laser releases energy and heat, restoring the tissues of the vaginal canal and vulva through the stimulation of collagen and elastin.
Studies have shown an increase in blood flow, increased lubrication, greater immune resistance to infections, and restoration of the strength and elasticity of the vaginal wall.
Typically, results are achieved immediately after the procedure. However, three sessions (one session every four weeks) are recommended to achieve the desired results.
It can be indicated for
FemiliLift can be performed by all women who are not pregnant. However, this treatment is ideal for patients who:
Suffer from vaginal laxity.
Suffer from postpartum urinary incontinence
Suffer from dryness, loss of elasticity, and discomfort during sexual intercourse due to menopause.
Suffer from premature menopause due to chemotherapy in cancer treatment.
Are not candidates for hormone replacement therapy due to estrogen-sensitive cancer.